Synlogic Inc (SYBX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Synlogic Inc (SYBX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8116
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Synlogic Inc (Synlogic), formerly TMC Therapeutics Inc is a clinical stage drug development company that develops novel class of living medicines for the treatment of rare and genetic metabolic diseases, by applying synthetic biology to probiotics. The company’s pipeline includes SYNB1020 a drug candidate used for the treatment of Urea cycle disorder and another candidate SYNB1618 to treat the Phenylketonuria. It also produces drugs based on its proprietary synthetic biology and microbiome platform for the treatment of diseases, including liver disease, inflammatory and immune disorders, and cancer. Its synthetic biotics are designed to make therapeutic effects throughout the body from an initial stage in the microbiome. The company works in partnership with pharmaceutical and biotechnology companies for novel drug development in major disease areas. Synlogic is headquartered in Cambridge, Massachusetts, the US.

Synlogic Inc (SYBX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synlogic Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Synlogic Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Synlogic Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Synlogic Raises USD42 Million in Series C Financing 11
Synlogic Raises USD40 Million in Series B Venture Financing 13
Synlogic Raises USD17 Million Financing 15
Synlogic Raises Funds through Venture Financing 16
Synlogic Raises Additional USD5 Million in Series A Venture Financing 17
Synlogic Raises USD29.4 Million in Series A Venture Financing 18
Partnerships 19
Synlogic Enters into Partnership Agreement with Ginkgo BioWorks 19
Synlogic Enters into R&D Agreement with AbbVie 20
Synlogic Enters into R&D Agreement with Pharmaceutical Company 21
Merger 22
Synlogic and Mirna Therapeutics Merges in Reverse Merger Transaction 22
Equity Offering 24
Synlogic Plans to Raise up to USD200 Million in Public Offering of Securities 24
Synlogic Raises USD30 Million in Public Offering of Shares 25
Synlogic Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD57.5 Million 27
Synlogic Inc – Key Competitors 29
Synlogic Inc – Key Employees 30
Synlogic Inc – Locations And Subsidiaries 31
Head Office 31
Recent Developments 32
Financial Announcements 32
Aug 08, 2018: Synlogic reports second quarter 2018 financial results and provides program updates 32
May 15, 2018: Synlogic Reports First Quarter 2018 Financial Results and Provides Business Update 34
Mar 20, 2018: Synlogic Reports Fourth Quarter and Full Year 2017 Financial Results 35
Nov 13, 2017: Synlogic Reports Third Quarter 2017 Financial Results and Recent Progress 37
Corporate Communications 39
Oct 02, 2018: Synlogic names Dr. Aoife Brennan as President and Chief Executive Officer 39
Oct 02, 2018: Synlogic names Dr. Aoife Brennan as President and Chief Executive Officer 40
May 10, 2018: Synlogic Announces Leadership Change 41
Oct 10, 2017: Synlogic Strengthens Leadership Team with Appointment of Chief Operating Officer and Chief Human Resources Officer 42
Product News 43
04/18/2018: Synlogic Doses First Subject in Phase 1/2a Trial of SYNB1618 for Treatment of Phenylketonuria 43
Product Approvals 44
Oct 24, 2017: Synlogic Receives Orphan Drug Designation for SYNB1618, a Synthetic Biotic Medicine for the Treatment of Phenylketonuria 44
Jun 26, 2017: Synlogic Receives Fast Track Designation in U.S. for Lead Candidate, SYNB1020 45
Clinical Trials 46
Mar 12, 2018: Synlogic Presents Preclinical Data on Synthetic Biotic Medicine SYNB1618 at Annual Meeting of The Society for Inherited Metabolic Disorders 46
Jan 05, 2018: Synlogic Provides Update on its Phenylketonuria Drug candidate SYNB1618 47
Jun 19, 2017: Synlogic Doses First Subject in Phase 1 Trial of Novel Class of Synthetic Biotic Medicines 48
Mar 22, 2017: Synlogic to Present at 2017 American College of Medical Genetics and Genomics Annual Meeting 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Synlogic Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synlogic Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synlogic Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Synlogic Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Synlogic Raises USD42 Million in Series C Financing 11
Synlogic Raises USD40 Million in Series B Venture Financing 13
Synlogic Raises USD17 Million Financing 15
Synlogic Raises Funds through Venture Financing 16
Synlogic Raises Additional USD5 Million in Series A Venture Financing 17
Synlogic Raises USD29.4 Million in Series A Venture Financing 18
Synlogic Enters into Partnership Agreement with Ginkgo BioWorks 19
Synlogic Enters into R&D Agreement with AbbVie 20
Synlogic Enters into R&D Agreement with Pharmaceutical Company 21
Synlogic and Mirna Therapeutics Merges in Reverse Merger Transaction 22
Synlogic Plans to Raise up to USD200 Million in Public Offering of Securities 24
Synlogic Raises USD30 Million in Public Offering of Shares 25
Synlogic Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD57.5 Million 27
Synlogic Inc, Key Competitors 29
Synlogic Inc, Key Employees 30

List of Figures
Synlogic Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synlogic Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Synlogic Inc (SYBX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • HSBC Trinkaus & Burkhardt Private Banking:企業の戦略・SWOT・財務情報
    HSBC Trinkaus & Burkhardt Private Banking - Strategy, SWOT and Corporate Finance Report Summary HSBC Trinkaus & Burkhardt Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • China Gas Holdings Ltd (384):企業の財務・戦略的SWOT分析
    China Gas Holdings Ltd (384) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Promius Pharma LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Promius Pharma LLC (Promius Pharma), a subsidiary of Dr. Reddy's Laboratories Ltd, is a designer of personal and practical health care solutions that provides dermatology and neurology products. The company provides dermatology and neurology products. Its products include clocortolone pivala …
  • DTE Energy Co (DTE)-エネルギー分野:企業M&A・提携分析
    Summary DTE Energy Company (DTE Energy) is a diversified energy company that develops and manages energy-related businesses and services. It has presence in the electricity value chain from generation, procurement, to transmission, distribution, and sales. The company procures, stores, and transport …
  • CooperSurgical Inc-医療機器分野:企業M&A・提携分析
    Summary CooperSurgical Inc (CooperSurgical), a subsidiary of The Cooper Companies Inc is a medical device company that offers surgical instrument. The company offers surgical products, clinic and office products, labor and delivery products, and critical care products. Its surgical products include …
  • Kernel Holding SA:企業の戦略・SWOT・財務情報
    Kernel Holding SA - Strategy, SWOT and Corporate Finance Report Summary Kernel Holding SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Axpo Holding AG-エネルギー分野:企業M&A・提携分析
    Summary Axpo Holding AG (Axpo) is an electricity utility that produces, trades and sells electricity. It is wholly owned by the cantons of Northeastern Switzerland. The company covers the entire value chain from power generation and marketing of a wide range of products to power distribution. It gen …
  • 88 Energy Ltd (88E):企業の財務・戦略的SWOT分析
    Summary 88 Energy Ltd (88 Energy), formerly Tangiers Petroleum Ltd, is an exploration and production company that develops oil-rich provinces. The company offers discovery, exploration and development of onshore oil projects. It has oil and gas assets in Morocco and Australia. 88 Energy’s Morocco pr …
  • Neurodyn Life Sciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Neurodyn Life Sciences Inc (Neurodyn Life Sciences), formerly Neurodyn Inc is a provider of validation and development of bioactives for neuroprotection and early treatment of neurological diseases. The company's products include neuroprotectant, memogain, progranulin, and nerve pain treatme …
  • Daimler AG (DAI):企業の財務・戦略的SWOT分析
    Daimler AG (DAI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • University of Chicago-製薬・医療分野:企業M&A・提携分析
    Summary University of Chicago (UOC) is an academic and research university that offers education and research in various disciplines. The university offers undergraduate, master’s and PhD programs in the areas of anthropology, art history, astronomy and astrophysics, biochemistry and molecular biolo …
  • Novartis India Ltd (500672):企業の財務・戦略的SWOT分析
    Summary Novartis India Ltd (Novartis), a subsidiary of Novartis AG, is a healthcare company that offers pharmaceuticals, generic medicine and eye care products. The company’s pharmaceutical division develops drugs in the therapeutic areas of bone and pain, calcium portfolio, gynecology, oncology and …
  • Society for Worldwide Interbank Financial Telecommunication:企業の戦略的SWOT分析
    Society for Worldwide Interbank Financial Telecommunication - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, k …
  • The Israel Electric Corporation Ltd:電力:M&Aディール及び事業提携情報
    Summary The Israel Electric Corporation Ltd (IECL) formerly Palestine Electric Corporation Ltd., is an integrated electric utility that carries out the generation, transmission, distribution, sale and supply of electricity. The State of Israel owns around 99.85% of the company. It generates power ma …
  • E.ON SE:発電所・企業SWOT分析
    E.ON SE - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives …
  • Oracle Corporation Japan (4716):企業の財務・戦略的SWOT分析
    Summary Oracle Corporation Japan (Oracle Corp) is an information technology company that offers software and hardware services. The company offers integrated cloud applications and platform services. It develops software and hardware products, solutions, consulting, support services, education busin …
  • Ascent Solar Technologies Inc (ASTI)-エネルギー分野:企業M&A・提携分析
    Summary Ascent Solar Technologies, Inc. (Ascent solar) is a developer and manufacturer of thin-film photovoltaic modules using substrate materials. It develops products by using thin-film copper-indium-gallium- diselenide (CIGS) photovoltaic technology. The product portfolio of the company includes …
  • Europ Assistance Holding SA:企業の戦略的SWOT分析
    Europ Assistance Holding SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Tien Phong Plastic (NTP):企業の財務・戦略的SWOT分析
    Tien Phong Plastic (NTP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Giraffas Administradora De Franquias Ltda:企業の戦略・SWOT・財務情報
    Giraffas Administradora De Franquias Ltda - Strategy, SWOT and Corporate Finance Report Summary Giraffas Administradora De Franquias Ltda - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆